Improvement in quality of life with omalizumab in patients with severe allergic asthma

References

• Suissa S, Ernst P, Boivin JF, Horwitz RI, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149:604–10
   PubMed Web of Science ®Google Scholar
• Tough SC, Hessel PA, Ruff M, Green FH, et al. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657–65
   PubMed Web of Science ®Google Scholar
• Bleeker E, Bresnahan B, Hayden ML, Warrent EH, Deniz Y. Asthma-related quality of life in patients with severe or difficult-to-treat asthma. Am J Respir Crit Care Med 2003;67:A114
   Google Scholar
• Hooi LN. What are the clinical factors that affect quality of life in adult asthmatics? Med J Malaysia 2003;58: 506–15
   PubMedGoogle Scholar
• Juniper EF, Wisniewski ME, Cox FM, Emmett AH, et al. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004;23:287–91
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2005
   Google Scholar
• Buhl R, Soler M, Matz J, Townley R, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73–8
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, McAlary M, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–90
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, Lotvall J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632–8
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–16
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, Liu J, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154–9
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, Buhl R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254–61
   Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709–17
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Ayre G, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701–8
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, Buhl R, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302–8
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Brookman L, Fox H, Johnson C, et al. Pharmaco-dynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491–8
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76–83
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832–8
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81–7
   PubMed Web of Science ®Google Scholar
• Berend N, Kellett B, Kent N, Sly PD. Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate. Respirology 2001;6:237–46
   PubMedGoogle Scholar
• Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New Engl J Med 2001;344:1594–602
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Nelson HS, Tierney WM, Babu AN, et al. Clinically important differences in health-related quality of life for patients with asthma: an expert consensus panel report. Ann Allergy Asthma Immunol 2003;91:148–53
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998;12:1209–18
   PubMed Web of Science ®Google Scholar
• Antonicelli L, Bucca C, Neri M, De Benedetto F, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723–9
   Google Scholar
• Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636–42
   PubMed Web of Science ®Google Scholar
• Serra-Batlles J, Plaza V, Morejon E, ComeIla A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322–6
   Google Scholar
• Fuhlbrigge AL, Adams RJ, Guilbert TW, Grant E, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002;166:1044–9
   PubMed Web of Science ®Google Scholar
• Yawn BP, Fryer GE, Lanier D. Asthma severity: the patient's perspective. J Asthma 2004;41:623–30
   PubMed Web of Science ®Google Scholar
• Jacobs JE, MaiIle AR, Akkermans RP, van Weel C, Grol RP. Assessing the quality of life of adults with chronic respiratory diseases in routine primary care: construction and first validation of the 10-Item Respiratory Illness Questionnaire-monitoring 10 (RIQ-MON10). Qual Life Res 2004;13: 1117–27
   Google Scholar
• Diette GB, Krishnan JA, Wolfenden LL, Skinner EA, et al. Relationship of physician estimate of underlying asthma severity to asthma outcomes. Ann Allergy Asthma Immunol 2004;93:546–52
   PubMed Web of Science ®Google Scholar
• Vollmer WM. Assessment of asthma control and severity. Ann Allergy Asthma Irnrnunol 2004;93:409–15
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, Busse WW, et al.; and the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836–44
   Google Scholar
• Ayre G, Fox H, Reisner C. Evaluating response to omalizumab therapy in clinical practice. J Allergy Chin Irnrnunol 2006;117: S10, 37
   Google Scholar